SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register-based cohort study.

IF 4.1 Q1 CLINICAL NEUROLOGY
Brain communications Pub Date : 2024-11-29 eCollection Date: 2024-01-01 DOI:10.1093/braincomms/fcae406
Scott Montgomery, Snieguole Vingeliene, Huiqi Li, Helena Backman, Ruzan Udumyan, Johan Jendeberg, Gunlög Rasmussen, Martin Sundqvist, Katja Fall, Ayako Hiyoshi, Fredrik Nyberg
{"title":"SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register-based cohort study.","authors":"Scott Montgomery, Snieguole Vingeliene, Huiqi Li, Helena Backman, Ruzan Udumyan, Johan Jendeberg, Gunlög Rasmussen, Martin Sundqvist, Katja Fall, Ayako Hiyoshi, Fredrik Nyberg","doi":"10.1093/braincomms/fcae406","DOIUrl":null,"url":null,"abstract":"<p><p>Demyelinating diseases including multiple sclerosis are associated with prior infectious exposures, so we assessed whether SARS-CoV-2 infection is associated with subsequent diagnoses of non-multiple sclerosis demyelinating diseases and multiple sclerosis. All residents of Sweden aged 3-100 years were followed between 1 January 2020 and 30 November 2022, excluding those with demyelinating disease prior to 2020, comprising 9 959 818 individuals divided into uninfected and those who were infected were categorized into those with and without hospital admission for the infection as a marker of infection severity. Cox regression assessed the risk of two separate outcomes: hospital diagnosed non-multiple sclerosis demyelinating diseases of the CNS and multiple sclerosis. The exposures were modelled as time-varying covariates (uninfected, infection without hospital admission and infected with hospital admission). Hospital admission for COVID-19 was associated with raised risk of subsequent non-multiple sclerosis demyelinating disease, but only 12 individuals had this outcome among the exposed, and of those, 7 has an unspecified demyelinating disease diagnosis. Rates per 100 000 person-years (and 95% confidence intervals) were 3.8 (3.6-4.1) among those without a COVID-19 diagnosis and 9.0 (5.1-15.9) among those admitted to hospital for COVID-19, with an adjusted hazard ratio and (and 95% confidence interval) of 2.35 (1.32-4.18, <i>P</i> = 0.004). Equivalent associations with multiple sclerosis (28 individuals had this outcome among the exposed) were rates of 9.5 (9.1-9.9) and 21.0 (14.5-30.5) and an adjusted hazard ratio of 2.48 (1.70-3.61, <i>P</i> < 0.001). Only a small number of non-multiple sclerosis demyelinating disease diagnoses were associated with hospital admission for COVID-19, and while the number with multiple sclerosis was somewhat higher, longer duration of follow-up will assist in identifying whether the associations are causal or due to shared susceptibility or surveillance bias, as these diseases can have long asymptomatic and prodromal phases.</p>","PeriodicalId":93915,"journal":{"name":"Brain communications","volume":"6 6","pages":"fcae406"},"PeriodicalIF":4.1000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/braincomms/fcae406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Demyelinating diseases including multiple sclerosis are associated with prior infectious exposures, so we assessed whether SARS-CoV-2 infection is associated with subsequent diagnoses of non-multiple sclerosis demyelinating diseases and multiple sclerosis. All residents of Sweden aged 3-100 years were followed between 1 January 2020 and 30 November 2022, excluding those with demyelinating disease prior to 2020, comprising 9 959 818 individuals divided into uninfected and those who were infected were categorized into those with and without hospital admission for the infection as a marker of infection severity. Cox regression assessed the risk of two separate outcomes: hospital diagnosed non-multiple sclerosis demyelinating diseases of the CNS and multiple sclerosis. The exposures were modelled as time-varying covariates (uninfected, infection without hospital admission and infected with hospital admission). Hospital admission for COVID-19 was associated with raised risk of subsequent non-multiple sclerosis demyelinating disease, but only 12 individuals had this outcome among the exposed, and of those, 7 has an unspecified demyelinating disease diagnosis. Rates per 100 000 person-years (and 95% confidence intervals) were 3.8 (3.6-4.1) among those without a COVID-19 diagnosis and 9.0 (5.1-15.9) among those admitted to hospital for COVID-19, with an adjusted hazard ratio and (and 95% confidence interval) of 2.35 (1.32-4.18, P = 0.004). Equivalent associations with multiple sclerosis (28 individuals had this outcome among the exposed) were rates of 9.5 (9.1-9.9) and 21.0 (14.5-30.5) and an adjusted hazard ratio of 2.48 (1.70-3.61, P < 0.001). Only a small number of non-multiple sclerosis demyelinating disease diagnoses were associated with hospital admission for COVID-19, and while the number with multiple sclerosis was somewhat higher, longer duration of follow-up will assist in identifying whether the associations are causal or due to shared susceptibility or surveillance bias, as these diseases can have long asymptomatic and prodromal phases.

SARS-CoV-2感染和随后脱髓鞘疾病的风险:基于国家登记的队列研究
包括多发性硬化症在内的脱髓鞘疾病与先前的感染暴露相关,因此我们评估了SARS-CoV-2感染是否与非多发性硬化症脱髓鞘疾病和多发性硬化症的后续诊断相关。在2020年1月1日至2022年11月30日期间,对所有3-100岁的瑞典居民进行了随访,不包括2020年之前患有脱髓鞘疾病的人,其中包括9959818人,分为未感染者和感染者,分为因感染而住院和未住院的人,作为感染严重程度的标志。Cox回归评估了两个独立结局的风险:医院诊断的非多发性硬化症中枢神经系统脱髓鞘疾病和多发性硬化症。暴露情况建模为时变协变量(未感染、未住院感染和住院感染)。因COVID-19入院与随后发生非多发性硬化症脱髓鞘疾病的风险增加有关,但在暴露者中只有12人出现这种结果,其中7人有未明确的脱髓鞘疾病诊断。在未诊断为COVID-19的患者中,发病率为每10万人年3.8(3.6-4.1),在因COVID-19住院的患者中,发病率为9.0(5.1-15.9),调整后的风险比(95%置信区间)为2.35 (1.32-4.18,P = 0.004)。与多发性硬化症的同等相关性(暴露者中有28人出现这种结果)为9.5(9.1-9.9)和21.0(14.5-30.5),调整后的风险比为2.48 (1.70-3.61,P < 0.001)。只有少数非多发性硬化症脱髓鞘疾病诊断与COVID-19住院相关,而多发性硬化症的数量略高,更长的随访时间将有助于确定这种关联是因果关系还是由于共同的易感性或监测偏差,因为这些疾病可能有很长的无症状和前体症状期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信